Vivimed Labs Gains 1.78%: Technical Shift and Upper Circuit Spark Interest

5 May: Upgrade to ‘Sell’ Reflects Technical Improvement Despite Weak Fundamentals

On 5 May 2026, Vivimed Labs Ltd’s rating was upgraded by MarketsMOJO from ‘Strong Sell’ to ‘Sell’, signalling a mild improvement in technical indicators. This upgrade came despite the company’s ongoing fundamental weaknesses, including a negative EBITDA of ₹-11.15 crores and a high debt-to-equity ratio of 9.51 times. The stock closed at Rs.6.78, up 0.30% from the previous day’s Rs.6.76, while the Sensex declined 0.09% that day.

The upgrade was driven by a shift in technical momentum, with daily moving averages turning mildly bullish and monthly MACD and KST indicators signalling potential for positive price movement. However, weekly indicators remained mixed, and the company’s financial performance remained flat with persistent losses and high leverage. The stock’s valuation remains risky, trading well below its 52-week high of Rs.23.94, reflecting market scepticism.

7 May: Upper Circuit Hit Signals Strong Buying Interest

Vivimed Labs Ltd surged to its upper circuit limit of Rs.7.02 on 7 May 2026, marking a maximum daily gain of 3.14%. The stock closed at Rs.6.90, outperforming the Pharmaceuticals & Drugs sector’s 0.18% gain and the Sensex’s 0.26% rise. This rally was driven by intense buying pressure, resulting in a regulatory freeze on further transactions and a build-up of unfilled demand.

Trading volume on 7 May was approximately 71,570 shares, with a turnover of ₹0.004995 crore. The stock’s delivery volume on 6 May was 16,840 shares, a 128.83% increase over the five-day average, indicating growing investor participation. Technically, the stock traded above its 5-day and 50-day moving averages, signalling short- and medium-term bullishness, though it remained below longer-term averages.

The upper circuit freeze reflects strong market optimism but also highlights the stock’s micro-cap status and associated volatility. Despite the recent price rally, the Mojo Score remains at 33.0 with a ‘Sell’ rating, underscoring ongoing fundamental concerns.

Daily Price Performance vs Sensex

Key Takeaways

Positive Signals: The upgrade to a ‘Sell’ rating from ‘Strong Sell’ on 5 May 2026 reflects a mild technical improvement, with daily and monthly indicators turning cautiously bullish. The upper circuit hit on 7 May demonstrates strong buying interest and short-term momentum, supported by increased delivery volumes and price gains above key moving averages.

Cautionary Notes: Despite technical optimism, Vivimed Labs continues to face significant fundamental challenges. The company’s negative EBITDA, high leverage with a debt-to-equity ratio of 9.51 times, and poor returns on equity highlight ongoing operational difficulties. The stock trades far below its 52-week high of Rs.23.94, indicating persistent valuation concerns. The micro-cap status also implies higher volatility and lower liquidity, warranting careful monitoring.

Conclusion

Vivimed Labs Ltd’s performance during the week ending 8 May 2026 was characterised by a modest 1.78% gain, outpacing the Sensex’s 1.25% rise. The week’s narrative was shaped by a technical upgrade and a strong price rally culminating in an upper circuit hit, signalling renewed market interest. However, the company’s fundamental weaknesses remain pronounced, and the ‘Sell’ rating reflects a cautious stance despite improved technical signals.

Investors should weigh the short-term momentum against the company’s financial challenges and micro-cap risks. Monitoring volume trends and price stability in coming sessions will be essential to assess whether the recent gains can be sustained or if volatility may increase. Overall, the week’s developments suggest a tentative recovery in sentiment, but fundamental headwinds continue to temper enthusiasm.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →